With respect to its predictive role, several retrospective analyses of tumour samples in CRC patients receiving anti-EGFR antibody treatment have shown that patients with mutated KRAS did not benefit from anti-EGFR therapy (Lievre et al, 2006; Amado et al, 2008). Here, EGFR is linked to neoplasm.